<DOC>
	<DOC>NCT00846963</DOC>
	<brief_summary>The purpose of this study is to determine whether ursodiol is effective in the treatment of parenteral nutrition associated cholestasis in neonates.</brief_summary>
	<brief_title>Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates</brief_title>
	<detailed_description>This is the first randomised controlled study that address the question of the role of ursodiol as treatment of cases of PNAC. It includes all neonates with stratification of less than and equal to 32 weeks or more than 32 weeks of gestation.</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Preterm or interm newborns hospitalized in neonatal care units at CHU SainteJustine between October 1st 2008 and October 1st 2011. Must be receiving parenteral nutrition (either partial or total) at the diagnosis of cholestasis. Parental Consent must be obtained. Active urinary tract infection Presence of clinical signs(acholic stool) of or ultrasound evidence of biliary tract anomalies. Positive TORCH infections(Toxoplasmosis, Other infections, Rubella, Cytomegalovirus, Herpes simplex virus) Known short bowel syndrome Known congenital hypothyroidism Known genetic disorders associated with cholestasis like galactosemia, phenylcytonuria, antitrypsin 1 deficiency... etc</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>parenteral nutrition associated cholestasis in neonates</keyword>
	<keyword>parenteral nutrition induced cholestasis in preterms</keyword>
	<keyword>Bile duct obstruction</keyword>
	<keyword>biliary stasis</keyword>
</DOC>